A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.

KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with ...

At ASCO, Eli Lilly, Genfleet Therapeutics and InxMed all presented new clinical data on KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), going after the same mutation and indication as ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

Vectibix (panitumumab), for treating KRAS G12C-mutated metastatic colorectal cancer (mCRC). The regulatory body approved Lumakras plus Vectibix for treating KRAS G12C-mutated mCRC in adult ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Lumakras and Vectibix combination approved for KRAS G12C-mutated mCRC after specific chemotherapy regimens. CodeBreaK 300 trial showed improved progression-free survival with Lumakras/Vectibix ...

In the article, Jaocbio disclosed, for the first time, the complete dataset of glecirasib in KRAS G12C mutant non-small cell lung cancer patients in the second line or above setting. The pivotal ...